证券代码：300759 证券简称：康龙化成 公告编号：2025-026 康龙化成（北京）新药技术股份有限公司 关于非执行董事辞职暨 补选公司第三届董事会非执行董事的公告 事会任期届满之日止。 胡柏风先生在任职期间勤勉尽责，致力于公司的规范运作和健康发展，并凭 借自身积累的丰富投资经验，为公司可持续发展提供了诸多宝贵建议，公司董事 会对胡柏风先生在任职期间为公司及董事会所做出的贡献表示衷心感谢！ 特此公告。 康龙化成（北京）新药技术股份有限公司董事会 2025 年 4 月 28 日 2 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第三届董事会第十四次会议，审议通过了《关于补选公司第三届董 事会非执行董事的议案》。胡柏风先生因本职工作调整，申请辞去公司第三届董 事会非执行董事及董事会战略委员会委员职务（第三届董事会原定任期至 2026 年 6 月 20 日），辞职后胡柏风先生将不再担任公司任何职务。胡柏风先生自愿继 续履行非执行董事及董事会战略委员会委员职责至公司股东 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-024 康龙化成（北京）新药技术股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）第三届董事 会第十四次会议于 2025 年 4 月 25 日上午 11：00 以通讯方式召开，本次会议通 知及会议材料于 2025 年 4 月 11 日以邮件形式向全体董事发出。会议应出席董事 8 名，实际出席董事 8 名。本次会议由公司董事长 Boliang Lou 博士主持，公司 部分高级管理人员列席了本次会议。本次会议的召集和召开符合《中华人民共和 国公司法》等有关法律、行政法规、部门规章、规范性文件和《康龙化成（北京） 新药技术股份有限公司章程》的规定。 二、董事会会议审议情况 与会董事审议并以记名投票方式通过了以下议案： （一）审议通过《关于 2025 年第一季度报告的议案》 董事会认为：公司编制的《2025 年第一季度报告》符合法律、行政法规、中 国证监会和深圳证券交易所的规定，报 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[4] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[4] - The adjusted net profit under non-IFRS was ¥349,441,031.17, a 3.14% increase from ¥338,816,299.13 in the previous year[4] - The company's cash flow from operating activities was ¥852,829,144.27, reflecting a 14.38% increase compared to ¥745,630,586.78 in the same period last year[4] - Total operating revenue for the current period reached ¥3,098,813,569.89, an increase of 15.9% compared to ¥2,670,740,738.16 in the previous period[24] - Net profit for the current period was ¥279,654,565.09, compared to ¥215,919,833.12 in the previous period, representing an increase of 29.5%[25] - Basic earnings per share increased by 33.54% year-on-year to RMB 0.1736, reflecting the growth in net profit[12] - Basic earnings per share increased to 0.1736 from 0.1300, marking a growth of 33.1%[26] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, with a gross margin of 45.54%, up from 44.14% year-on-year[5] - Revenue from CMC (small molecule CDMO) services increased by 30.44% to ¥693,023,486.59, with a gross margin of 30.44%[5] - Revenue from clinical research services was ¥447,320,929.08, showing an 11.76% increase year-on-year[5] - Revenue from North American clients was ¥200,338.79 million, a 16.81% increase, accounting for 64.65% of total revenue[7] - The company signed new orders with a year-on-year growth of over 10%, particularly in laboratory services and CMC services[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥24,332,822,720.98, a 1.69% increase from ¥23,927,398,321.23 at the end of the previous year[4] - Total current assets decreased to CNY 7,384,443,685.17 from CNY 7,608,179,522.72, representing a decrease of approximately 2.95%[21] - Long-term equity investments increased to CNY 727,361,422.75 from CNY 648,983,149.15, an increase of about 12.06%[21] - Total liabilities increased to CNY 7,206,443,000.00, reflecting a growth of approximately 3.5% compared to the previous period[21] - The total liabilities decreased slightly to ¥9,686,700,206.35 from ¥9,704,526,037.38, a reduction of 0.2%[23] Expenses and Taxation - Research and development expenses increased by 30.56% year-on-year to RMB 122,210,590.15, indicating a continued commitment to R&D investment[12] - Total income tax expenses rose by 59.27% year-on-year to RMB 83,932,205.84, corresponding to the increase in total profit[13] - The company paid $1,398,959,106.45 to employees, an increase from $1,313,660,048.35[29] - The company reported a total tax payment of $146,967,843.36, a decrease from $155,141,776.68[29] Comprehensive Income - Other comprehensive income surged by 1,370.30% year-on-year to RMB 98,545,941.98, mainly due to increases in foreign currency translation differences and cash flow hedging[12] - Other comprehensive income after tax for the current period was ¥110,016,172.44, compared to a loss of ¥53,277,635.07 in the previous period[26] - The company reported a total comprehensive income of ¥389,670,737.53, up from ¥162,642,198.05, indicating a significant increase of 139.5%[26] Cash Flow - Cash inflow from operating activities totaled ¥3,472,049,631.92, compared to ¥3,137,994,335.42 in the previous period, indicating a rise of 10.7%[28] - The net cash flow from operating activities was $852,829,144.27, an increase of 14.4% compared to $745,630,586.78 in the previous period[29] - The total cash outflow from investing activities was $2,181,721,151.04, up from $1,578,554,143.99, resulting in a net cash flow from investing activities of -$1,212,095,238.52[29] - Cash inflow from financing activities was $148,201,518.67, compared to $104,094,412.63 in the previous period, while cash outflow was $247,128,234.59, down from $1,616,695,006.87[29] - The ending balance of cash and cash equivalents was $1,173,579,263.69, down from $4,561,507,266.77[29] Future Plans and Investments - The company plans to invest in new product development and market expansion strategies in the upcoming fiscal year[18] - The company is collaborating with professional institutions for equity investments, indicating a strategic move towards enhancing its investment portfolio[18] - The company has announced a profit distribution plan for the fiscal year 2024, which is expected to be disclosed in detail soon[18] Miscellaneous - The company did not execute any new accounting standards adjustments for the first quarter report[30] - The first quarter report was not audited[30]

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2025-03 问：请问目前中美关税情况对公司是否有影响？ 答：截至目前，美国加征关税对公司业务产生的影响有限。公司主要 是为客户提供研发服务，CMC 涉及的商业化货物出口的业务占比较 小，目前公司并未收到客户或其他合作伙伴向公司反馈关税问题对业 务合作造成影响。对于宏观的不确定性风险，公司会密切关注相关政 策动向。地缘政治背景下，也敬请投资者注意投资风险。 问：小分子 CDMO 产能利用率和毛利率趋势？ 答：从目前公司管线看，预计公司交付项目和收入规模会进一步提 高，产能利用率和毛利率也会同比提升。 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 √路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及 | | | 人员姓名 | Manulife、TruMed、SinoPac、Library Group、华凯资产管理 | | 时 间 | 年 月 日 2025 4 24 | | ...

Group 1: Market Trends and Projections - The global and Chinese pharmaceutical industry demand is expected to continue increasing, driven by the pursuit of health and longevity [2] - By 2030, the scale of drug research and production outsourcing services in China is projected to reach 482.3 billion RMB, with a market share of approximately 19.5% [3] Group 2: Impact of Tariffs and Geopolitical Factors - The impact of U.S. tariffs on the company's business has been limited, as the export of commercialized goods related to CMC constitutes a small portion of operations [3] - The company will closely monitor policy developments and geopolitical risks, advising investors to remain aware of investment risks [2][3] Group 3: Domestic Market Dynamics - The Chinese healthcare system has significantly increased its payment support for innovative drugs, with the proportion of innovative drug payments in overall healthcare spending showing notable improvement in recent years [2] - Chinese companies are increasingly demonstrating global competitiveness through various strategies such as licensing, NewCo formations, and mergers and acquisitions to access global markets [2]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company has shown a strong performance in its CDMO (Contract Development and Manufacturing Organization) business, with new orders for small molecule CDMO services increasing by over 35% [1] - The company's revenue for 2024 reached 12.276 billion yuan, representing a year-over-year increase of 6.39%, while the adjusted Non-GAAP net profit was 1.607 billion yuan, down 15.58% year-over-year [1] - The company expects new orders to grow by over 20% year-over-year in 2024, with laboratory services and CMC/CDMO services contributing significantly to this growth [1] Summary by Sections Business Performance - The company reported a strong revenue growth in Q4 2024, with laboratory services generating 7.047 billion yuan (up 5.81% year-over-year) and CMC/CDMO services achieving 2.989 billion yuan (up 10.24% year-over-year) [2] - The CMC/CDMO segment saw a significant increase in new orders, with 1,066 drug molecules or intermediates involved, including 19 projects in the process validation and commercialization stage [2] Clinical Research Services - The company generated 1.826 billion yuan from clinical research services in 2024, reflecting a year-over-year increase of 5.12% [3] - The number of ongoing clinical trial projects reached 1,062, including 94 Phase III trials, indicating a growing market share [3] Profitability - The overall gross margin for the company was 34.24%, a decrease of 1.51 percentage points year-over-year, with laboratory services and CMC/CDMO margins showing improvements in Q4 2024 [4] - The adjusted net profit margin for Q4 2024 was 14.43%, indicating a continued upward trend in profitability [4] Earnings Forecast and Valuation - The company forecasts EPS of 1.13, 1.31, and 1.52 yuan for 2025, 2026, and 2027 respectively, with a PE ratio of 20 times based on the closing price on April 15, 2025 [5]

康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年4月25日（星期五）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2025年3月31日止三個月之第一季度業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 董事會會議通告 中華人民共和國，北京 2025年4月11日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事胡柏風先生及李家慶先生；獨立非執行董事李麗華女士、曾坤鴻先生及 余堅先生。 ...

康龙化成（北京）新药技术股份有限公司 关于参与私募股权投资基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、投资事项概述 证券代码：300759 证券简称：康龙化成 公告编号：2025-023 （6）成立日期：2025 年 3 月 25 日 （1）统一社会信用代码：91330201MAEEWL4Y0R （2）名称：宁波甬康股权投资合伙企业（有限合伙） （7）出资额：11,401 万元人民币 为充分运用专业投资机构在行业内投资、研判的能力，提高康龙化成（北京） 新药技术股份有限公司（以下简称"公司"）投资能力，同时促进宁波医药行业 的高质量发展，公司作为有限合伙人参与投资宁波甬康股权投资合伙企业（有限 合伙）（以下简称"基金"）。2025 年 3 月 19 日，公司签署了《关于宁波甬康 股权投资合伙企业（有限合伙）（拟）之有限合伙协议》。具体内容详见公司于 2025 年 3 月 20 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于参与 私募股权投资基金的公告》（公告编号：2025-010）。 二、基金进展情况 近 ...

Group 1 - The core viewpoint of the news is that the CSI Medical Index has shown fluctuations, with a recent increase of 1.73% despite a decline of 11.00% over the past month [1] - The CSI Medical Index reflects the overall performance of listed companies in the medical and healthcare sector, including medical devices, services, and information technology [1] - The index has a base date of December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI Medical Index include WuXi AppTec (9.9%), Mindray Medical (9.27%), and Aier Eye Hospital (8.27%) [1] - The market share of the CSI Medical Index holdings is 57.98% from the Shenzhen Stock Exchange and 42.02% from the Shanghai Stock Exchange [1] - The industry composition of the CSI Medical Index holdings shows that 97.49% is in healthcare, 2.25% in information technology, and 0.26% in consumer goods [1] Group 3 - The index sample is adjusted every six months, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to specific calculation and maintenance guidelines [2]

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a significant decline, with major companies reporting substantial drops in stock prices [1] - Kanglong Chemical (03759.HK) saw a decrease of 13.27%, while Tigermed (03347.HK) fell by 11.33% [1] - Other notable declines included WuXi Biologics (02269.HK) down 8.19%, Kelaiying (06821.HK) down 7.52%, and WuXi AppTec (02359.HK) down 5.64% [1]